Stocks · News reference
Keefe, Bruyette & Woods analyst Paul Johnson maintains Sixth Street Specialty (NYSE:TSLX) with a Outperform and raises the price target from $18.5 to $19.5.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Sixth Street Specialty (NYSE:TSLX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. This is a 23.21 percent decrease over earnings of $0.56 per share
Read original at benzingaBridgeBio Pharma announced a $1 billion preferred equity investment led by Sixth Street ($800M) and HealthCare Royalty ($133.9M). The Series A Cumulative Convertible Preferred Stock features a 7% dividend and conversion price of $137.79 per share (100%+ premium to 30-day VWAP). The capital strengthens BridgeBio's balance sheet as it prepares for potential launches of three blockbuster drugs: BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia, while Attruby continues to grow as a multi-billion-dollar drug.
Read original at globenewswire-inc